These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11342095)

  • 1. Low-molecular-weight heparin prophylaxis: preoperative versus postoperative initiation in patients undergoing elective hip surgery.
    Hull RD; Pineo GF; MacIsaac S
    Thromb Res; 2001 Jan; 101(1):V155-62. PubMed ID: 11342095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators.
    Hull RD; Pineo GF; Francis C; Bergqvist D; Fellenius C; Soderberg K; Holmqvist A; Mant M; Dear R; Baylis B; Mah A; Brant R
    Arch Intern Med; 2000 Jul; 160(14):2199-207. PubMed ID: 10904464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review.
    Hull RD; Pineo GF; Stein PD; Mah AF; MacIsaac SM; Dahl OE; Ghali WA; Butcher MS; Brant RF; Bergqvist D; Hamulyák K; Francis CW; Marder VJ; Raskob GE
    Arch Intern Med; 2001 Sep; 161(16):1952-60. PubMed ID: 11525697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery?
    Strebel N; Prins M; Agnelli G; Büller HR
    Arch Intern Med; 2002 Jul; 162(13):1451-6. PubMed ID: 12090880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators.
    Hull RD; Pineo GF; Francis C; Bergqvist D; Fellenius C; Soderberg K; Holmqvist A; Mant M; Dear R; Baylis B; Mah A; Brant R
    Arch Intern Med; 2000 Jul; 160(14):2208-15. PubMed ID: 10904465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement.
    Hull RD; Brant RF; Pineo GF; Stein PD; Raskob GE; Valentine KA
    Arch Intern Med; 1999 Jan; 159(2):137-41. PubMed ID: 9927095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty.
    Freedman KB; Brookenthal KR; Fitzgerald RH; Williams S; Lonner JH
    J Bone Joint Surg Am; 2000 Jul; 82-A(7):929-38. PubMed ID: 10901307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparin: the optimal duration of prophylaxis against postoperative venous thromboembolism after total hip or knee replacement.
    Heit JA
    Thromb Res; 2001 Jan; 101(1):V163-73. PubMed ID: 11342096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose relation in the prevention of proximal vein thrombosis with a low molecular weight heparin (tinzaparin) in elective hip arthroplasty.
    Lassen MR; Borris LC; Jensen HP; Poulsen KA; Ejstrud P; Andersen BS
    Clin Appl Thromb Hemost; 2000 Jan; 6(1):53-7. PubMed ID: 10726050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery.
    Raskob GE; Hirsh J
    Chest; 2003 Dec; 124(6 Suppl):379S-385S. PubMed ID: 14668421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
    Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
    Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
    Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
    Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin.
    Francis CW; Pellegrini VD; Totterman S; Boyd AD; Marder VJ; Liebert KM; Stulberg BN; Ayers DC; Rosenberg A; Kessler C; Johanson NA
    J Bone Joint Surg Am; 1997 Sep; 79(9):1365-72. PubMed ID: 9314399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.
    Hull R; Raskob G; Pineo G; Rosenbloom D; Evans W; Mallory T; Anquist K; Smith F; Hughes G; Green D
    N Engl J Med; 1993 Nov; 329(19):1370-6. PubMed ID: 8413432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based evaluation of preoperative vs postoperative use of low-molecular-weight heparin in preventing deep vein thrombosis in elective hip surgery.
    Ghosh A
    Arch Intern Med; 1999 Jul; 159(14):1622-3. PubMed ID: 10421287
    [No Abstract]   [Full Text] [Related]  

  • 18. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review.
    Hull RD; Pineo GF; Stein PD; Mah AF; MacIsaac SM; Dahl OE; Butcher M; Brant RF; Ghali WA; Bergqvist D; Raskob GE
    Ann Intern Med; 2001 Nov; 135(10):858-69. PubMed ID: 11712876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty.
    Anderson DR; O'Brien BJ; Levine MN; Roberts R; Wells PS; Hirsh J
    Ann Intern Med; 1993 Dec; 119(11):1105-12. PubMed ID: 8239230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.